EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

Shukui Qin iD, Jin Li, Yuxian Bai iD, Zishu Wang, Zhendong Chen iD, Ruihua Xu iD, Jianming Xu iD, Hongmei Zhang iD, Jia Chen, Ying Yuan iD, Tianshu Liu, Lin Yang iD und 13 weitere

Journal of Clinical Oncology · 20.11.2023 · 41 (33) · 5163-5173

DOI: 10.1200/jco.22.02630 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2023. Verfasst von Shukui Qin und 24 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center of Jinling Hospital, Nanjing, China. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

K-Ras pancreatic cancers benefit overall survival in phase 3 NOTABLE study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabinePancreatic NeoplasmsHumansDeoxycytidineAntibodies, Monoclonal, HumanizedDisease ProgressionAntineoplastic Combined Chemotherapy Protocols

Substanzen

GemcitabinenimotuzumabDeoxycytidineAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Cancer Center of Jinling Hospital, Nanjing, China.
  • Shanghai East Hospital, Shanghai, China.
  • Harbin Medical University Cancer Hospital, Harbin, China.
  • The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
  • The Second Hospital of Anhui Medical University, Hefei, China.
  • Cancer Center of Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Shukui Qin, Yuxian Bai, Zhendong Chen, Ruihua Xu, Jianming Xu, Hongmei Zhang, Ying Yuan, Lin Yang, Lin Shen, Ying Cheng, Jun Zhang

Zitieren

APA

Qin, S., Li, J., Bai, Y., Wang, Z., Chen, Z., Xu, R., Xu, J., Zhang, H., Chen, J., Yuan, Y., Liu, T., Yang, L., Zhong, H., Chen, D., Shen, L., Hao, C., Fu, D., Cheng, Y., Yang, J., …, & Zheng, Q. (2023). Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 41(33), 5163-5173. https://doi.org/10.1200/jco.22.02630

Vancouver

Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, et al. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Journal of Clinical Oncology. 2023;41(33):5163-5173. doi:10.1200/jco.22.02630

BibTeX
@article{Qin2023,
  author = {Qin, Shukui and Li, Jin and Bai, Yuxian and Wang, Zishu and Chen, Zhendong and Xu, Ruihua and Xu, Jianming and Zhang, Hongmei and Chen, Jia and Yuan, Ying and Liu, Tianshu and Yang, Lin and Zhong, Haijun and Chen, Donghui and Shen, Lin and Hao, Chunyi and Fu, Deliang and Cheng, Ying and Yang, Jianwei and Wang, Qiong and Qin, Baoli and Pan, Hongming and Zhang, Jun and Bai, Xianhong and Zheng, Qingshan},
  title = {Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {33},
  pages = {5163--5173},
  doi = {10.1200/jco.22.02630}
}
Kostenlos starten →